In 2007, the FDA approved Elelyso (taliglucerase alfa) for long-term enzyme replacement therapy to treat a form of Gaucher disease, a rare genetic disorder.

Elelyso is manufactured and distributed by New York City-based Pfizer, under license from Protalix BioTherapeutics.